The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma
Heng Ma, Xianlong Chen, Shengwei Mo, Xinxin Mao, Jingci Chen, Yilin Liu, Zhaohui Lu, Shuangni Yu, Jie Chen
Abstract
Our findings suggest that targeting TIGIT/CD155 immunosuppressive axis may guide patient stratification and improve the clinical outcome of PDAC.
Topics & Concepts
TIGITImmune systemCancer researchCD8Tumor microenvironmentFOXP3T cellMedicineCytotoxic T cellCD3ImmunologyBiologyIn vitroBiochemistryCancer Immunotherapy and BiomarkersImmune Cell Function and InteractionImmune cells in cancer